Our Top 5 Podcast Episodes of 2024

1. Healthcare Marketing Strategies for Reaching Diverse Audiences

Amanda Powers-Han, Chief Marketing Officer, Greater Than One discusses:

• How improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes
• Challenges healthcare marketers face in crafting culturally sensitive messages that resonate with diverse audiences and address their specific healthcare needs
• Other tactics can healthcare marketers utilize to ensure their outreach goes beyond visuals to truly connect with diverse audiences on a deeper level
• Their 501c3, Greater Good and it's arm, Honeycomb Health

2. Cell and Gene Therapy Check-in 2024

Fran Gregory, Vice President of Emerging Therapies at Cardinal Health, gives insight into:

• Recent trends in the cell and gene therapy space
• How CAR-T therapies have been gaining momentum and what kind of progress we can expect in the next 10 years
• Personalized medicine and gene editing advances
• The biggest hurdles within cell and gene therapy space and how do we begin to jump over them
• Patient advocacy
• The biggest foci for cell and gene therapy for the next five years

3. The Weight-Loss Gold Rush: Legal and Regulatory Implications

Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses:

• Top legal and regulatory concerns for investors considering when financing companies developing or marketing GLP-1 drugs
• How the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs
• What needs to be done for GLP-1s to be covered
• Steps companies developing weight-loss medications should take to ensure responsible and ethical practice
• Advice for investors and financiers who are considering entering the weight-loss medication market

4. Gen-Z Influence on Pharma M&A

Ian Baer, Founder and Chief Soothsayer, Sooth, discusses:

• His companies recent data and research about some massive behavioral shifts occurring across Gen-Z
• How pharmaceutical companies and healthcare advertising agencies can adapt their strategies to attract the ever elusive generation.

5. Recent Licensing Agreement Poised to Advance Company ADC

Jingsong Wang, Chairman of Nona Biosciences, discusses:

• Nona Biosciences’ recent exclusive license agreement with Pfizer Inc. for the development and commercialization of HBM9033, an innovative antibody-drug conjugate (ADC) targeting MSLN, a key antigen in various solid tumors. Wang believes that the partnership will significantly advance Nona's Harbour Mice® platform and ADC ecosystem.